| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f21c1009c60308a64b8e7dc0bb989632 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-252
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-256
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2420-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2300-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L33-0082
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-556
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1767
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L33-128
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-643
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L33-0041
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L33-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
| filingDate |
2012-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_96bad56dec89946b519c769c4a850e29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5f3186aabda571cc88e21228823e8d1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11910dc6a8717b92a377f947348854b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de2ff643fb1becde1485d60680a80a8d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed1635f341609c0cab65f8536687f770 |
| publicationDate |
2017-12-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
ES-2646191-T3 |
| titleOfInvention |
Factor XII inhibitors for administration with medical procedures comprising contact with artificial surfaces |
| abstract |
FXII / FXIIa inhibitor for use in the prevention of thrombus formation and / or stabilization during and / or after a medical procedure carried out on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, where said FXII / FXIIa inhibitor is administered before and / or during and / or after said medical procedure and also where (i) the artificial surface is exposed to at least 80% of the subject's blood volume and the artificial surface is at least 0.2 m2 or (ii) the artificial surface is a vessel for blood collection outside the subject's body or (iii) the artificial surface is a stent, valve, intraluminal catheter or a pumping system of internal assisted blood, where the FXII / FXIIa inhibitor comprises (i) the naturally occurring Infestin-4 polypeptide sequence (SEQ ID NO: 1) or a variant thereof, where a variant comprises (a) the amino acids N-terminal 2-13 of the naturally occurring Infestin-4 sequence and at least one and up to five amino acid mutations outside said N-terminal amino acids that give rise to differences with respect to the naturally occurring Infestin-4 sequence; and / or (b) six conserved cysteine residues of the naturally occurring Infestin-4 sequence and a homology of at least 70% with respect to the naturally occurring Infestin-4 sequence. (ii) SPINK-1 (SEQ ID NO: 2), which is mutated to include N-terminal amino acids 2-13 of the naturally occurring Infestin-4 sequence, or a variant of said mutated SPINK-1, where a variant comprises (a) the N-terminal amino acids 2-13 of the naturally occurring Infestin-4 sequence and at least one and up to five amino acid mutations outside of said N-terminal amino acids that give rise to differences with respect to the sequence of SPINK-1 of natural origin and that increase the homology of the variant with respect to the sequence of Infestina-4 of natural origin; and / or (b) six cysteine residues conserved from the naturally occurring SPINK-1 sequence and at least 70% homology to the naturally occurring SPINK-1 sequence. (iii) an anti-FXII / FXIIa antibody, where the antibody binds to FXII / FXIIa and inhibits its activity and / or activation. |
| priorityDate |
2011-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |